Prospective Phase II Study of Neoadjuvant Therapy with Cisplatin, 5-Fluorouracil, and Bevacizumab for Locally Advanced Resectable Esophageal Cancer

Publisher： Karger

E-ISSN： 2296-5262|35|7-8|427-431

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.7-8, 2012-07, pp. : 427-431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 101-108

Karger

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy with Sequential Methotrexate and 5-Fluorouracil Scheduling, Epirubicin and Cisplatin for Locally Advanced Bladder Cancer

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 1-5

Karger

Access to resources Recommend Favorite

Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907)

By  

Oncology, Vol. 89, Iss. 3, 2015-04 ,pp. : 143-151

Karger

Access to resources Recommend Favorite

Phase II Trial of Vinorelbine, Cisplatin and Continuous Infusion of 5-Fluorouracil Followed by Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer

By  

Oncology, Vol. 63, Iss. 2, 2002-09 ,pp. : 115-123

Karger

Access to resources Recommend Favorite

Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 215-221

Karger

Access to resources Recommend Favorite